MedTrace Logo

Intravenous Tenecteplase Plus EVT Versus EVT Alone on 4.5 to 24 Hours After Basilar Artery Occlusion

NCT05701956 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2026-02-18

No results posted yet for this study

Summary

To assess the effect of intravenous tenecteplase plus endovascular thrombectomy (EVT) compared to EVT alone on 4.5 to 24 hours after stroke due to basilar artery occlusion.

Conditions

  • Basilar Artery Occlusion
  • Acute Cerebrovascular Accident
  • Stroke Due to Basilar Artery Occlusion

Interventions

DRUG

Tenecteplase

Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds) before endovascular thrombectomy

PROCEDURE

Endovascular thrombectomy

The choice of endovascular thrombectomy strategy will be made by the treating neurointerventionist. All thrombectomy devices for endovascular treatment, which are approved by CFDA for this purpose, are allowed in the trial.

Sponsors & Collaborators

  • The First Affiliated Hospital of University of Science and Technology of China

    lead OTHER

Principal Investigators

  • Wei Hu, MD · The First Affiliated Hospital of University of Science and Technology of China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-16
Primary Completion
2025-02-04
Completion
2025-05-04

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05701956 on ClinicalTrials.gov